InSilico Medicine Cayman TopCo (FRA:O15) Institutional Ownership: 9.91% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Institutional Ownership?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 Institutional Ownership is 9.91% as of Aug. 27, 2026. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InSilico Medicine Cayman TopCo's institutional ownership is 9.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InSilico Medicine Cayman TopCo's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InSilico Medicine Cayman TopCo's Float Percentage Of Total Shares Outstanding is 0.00%.

InSilico Medicine Cayman TopCo Institutional Ownership Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Institutional Ownership Chart

InSilico Medicine Cayman TopCo Historical Data

The historical data trend for InSilico Medicine Cayman TopCo can be seen below:

2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 8.81 8.64 8.66 8.72 9.29 9.30 10.18 9.91
FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 9.91% mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Institutional Ownership of 9.91% as of Aug. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Institutional Ownership too high?
InSilico Medicine Cayman TopCo's current Institutional Ownership is 9.91%. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Institutional Ownership compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's Institutional Ownership of 9.91% can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Software company?
A good Institutional Ownership depends on the Software industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Institutional Ownership is 9.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Institutional Ownership of 9.91%. The current Institutional Ownership is 9.91%. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Institutional Ownership is 9.91% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price